Parcopa

Manganese Poisoning, Carbon Monoxide Poisoning, Parkinson's Disease + 3 more
Treatment
8 FDA approvals
20 Active Studies for Parcopa

What is Parcopa

CarbidopaThe Generic name of this drug
Treatment SummaryCarbidopa is a medication used to treat nausea in patients who do not respond to the combination therapy of levodopa and carbidopa. It works by blocking an enzyme called aromatic amino acid decarboxylase (DDC). Carbidopa does not cross the blood-brain barrier, so it must be taken with levodopa in order to be effective. Products containing solely carbidopa were first developed by Amerigens Pharmaceuticals Ltd and approved by the FDA in 2014. The combination treatment of carbidopa/levodopa was originally developed by Watson Labs but was approved by the FDA in 1992.
Sinemetis the brand name
image of different drug pills on a surface
Parcopa Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Sinemet
Carbidopa
1975
299

Approved as Treatment by the FDA

Carbidopa, also called Sinemet, is approved by the FDA for 8 uses which include Manganese Poisoning and Parkinson's Disease (PD) .
Manganese Poisoning
Used to treat manganese intoxication in combination with Levodopa
Parkinson's Disease (PD)
Used to treat Parkinson's Disease (PD) in combination with Levodopa
Parkinsonism post encephalitic
Used to treat Parkinsonism post encephalitic in combination with Levodopa
carbon monoxide intoxication
Used to treat carbon monoxide intoxication in combination with Levodopa
levodopa-driven nausea and vomiting
Parkinson's Disease
Used to treat Parkinson's Disease (PD) in combination with Levodopa
Carbon Monoxide Poisoning
Used to treat carbon monoxide intoxication in combination with Levodopa
Parkinson Disease
Used to treat Symptomatic Parkinson Disease in combination with Levodopa

Effectiveness

How Parcopa Affects PatientsCarbidopa is a drug that is often taken with levodopa to treat Parkinson's disease. When taken together, carbidopa helps levodopa enter the brain more easily and increases its effectiveness. Carbidopa also helps levodopa stay in the body longer and reduces the amount of levodopa that is converted to dopamine before it reaches the brain. Taking carbidopa with levodopa has been linked to fewer side effects, such as nausea, and a decrease in the amount of levodopa needed to treat Parkinson's Disease. The effect of carbidopa is not affected by the dose.
How Parcopa works in the bodyCarbidopa blocks an enzyme called DDC from breaking down levodopa. DDC is found in the bloodstream and in the brain, but Carbidopa cannot cross the blood-brain barrier. By blocking the enzyme in the bloodstream, Carbidopa prevents levodopa from being broken down before it can reach the brain, where it can be used to make dopamine.

When to interrupt dosage

The measure of Parcopa is contingent upon the diagnosed condition, including Symptomatic Parkinson Disease, carbon monoxide intoxication and Parkinson's Disease. The amount of dosage fluctuates as per the method of delivery featured in the table beneath.
Condition
Dosage
Administration
Manganese Poisoning
10.0 mg, 25.0 mg, , 50.0 mg, 31.25 mg, 37.5 mg, 12.5 mg, 18.75 mg, 23.75 mg, 48.75 mg, 61.25 mg, 36.25 mg, 4.63 mg/mL, 43.75 mg, 5.0 mg/mL
, Oral, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Enteral, Gel, Gel - Enteral, Capsule, extended release, Capsule, extended release - Oral, Suspension, Suspension - Enteral
Carbon Monoxide Poisoning
10.0 mg, 25.0 mg, , 50.0 mg, 31.25 mg, 37.5 mg, 12.5 mg, 18.75 mg, 23.75 mg, 48.75 mg, 61.25 mg, 36.25 mg, 4.63 mg/mL, 43.75 mg, 5.0 mg/mL
, Oral, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Enteral, Gel, Gel - Enteral, Capsule, extended release, Capsule, extended release - Oral, Suspension, Suspension - Enteral
Parkinson's Disease
10.0 mg, 25.0 mg, , 50.0 mg, 31.25 mg, 37.5 mg, 12.5 mg, 18.75 mg, 23.75 mg, 48.75 mg, 61.25 mg, 36.25 mg, 4.63 mg/mL, 43.75 mg, 5.0 mg/mL
, Oral, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Enteral, Gel, Gel - Enteral, Capsule, extended release, Capsule, extended release - Oral, Suspension, Suspension - Enteral
Parkinson Disease
10.0 mg, 25.0 mg, , 50.0 mg, 31.25 mg, 37.5 mg, 12.5 mg, 18.75 mg, 23.75 mg, 48.75 mg, 61.25 mg, 36.25 mg, 4.63 mg/mL, 43.75 mg, 5.0 mg/mL
, Oral, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Enteral, Gel, Gel - Enteral, Capsule, extended release, Capsule, extended release - Oral, Suspension, Suspension - Enteral
levodopa-driven nausea and vomiting
10.0 mg, 25.0 mg, , 50.0 mg, 31.25 mg, 37.5 mg, 12.5 mg, 18.75 mg, 23.75 mg, 48.75 mg, 61.25 mg, 36.25 mg, 4.63 mg/mL, 43.75 mg, 5.0 mg/mL
, Oral, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Enteral, Gel, Gel - Enteral, Capsule, extended release, Capsule, extended release - Oral, Suspension, Suspension - Enteral
Parkinsonism post encephalitic
10.0 mg, 25.0 mg, , 50.0 mg, 31.25 mg, 37.5 mg, 12.5 mg, 18.75 mg, 23.75 mg, 48.75 mg, 61.25 mg, 36.25 mg, 4.63 mg/mL, 43.75 mg, 5.0 mg/mL
, Oral, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Enteral, Gel, Gel - Enteral, Capsule, extended release, Capsule, extended release - Oral, Suspension, Suspension - Enteral

Warnings

Parcopa has two contraindications and should not be administered for the ailments enumerated in the following table.Parcopa Contraindications
Condition
Risk Level
Notes
Pulse Frequency
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Carbidopa may interact with Pulse Frequency
There are 20 known major drug interactions with Parcopa.
Common Parcopa Drug Interactions
Drug Name
Risk Level
Description
Abacavir
Minor
Carbidopa may decrease the excretion rate of Abacavir which could result in a higher serum level.
Acetaminophen
Minor
Carbidopa may decrease the excretion rate of Acetaminophen which could result in a higher serum level.
Aclidinium
Minor
Carbidopa may decrease the excretion rate of Aclidinium which could result in a higher serum level.
Acrivastine
Minor
Carbidopa may decrease the excretion rate of Acrivastine which could result in a higher serum level.
Albutrepenonacog alfa
Minor
Carbidopa may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.
Parcopa Toxicity & Overdose RiskThe toxic dose of carbidopa in rats has been found to be 4810mg/kg. Animal studies have not shown any negative effects on fertility or development. In case of an overdose, it is recommended to immediately perform gastric lavage and give intravenous fluids. Additionally, continuous monitoring of the heart rate is advised.
image of a doctor in a lab doing drug, clinical research

Parcopa Novel Uses: Which Conditions Have a Clinical Trial Featuring Parcopa?

Currently, 49 active studies are investigating the potential of Parcopa as a treatment for post-encephalitic Parkinsonism, levodopa-induced nausea and vomiting, and manganese intoxication.
Condition
Clinical Trials
Trial Phases
Parkinson's Disease
40 Actively Recruiting
Not Applicable, Phase 1, Phase 4, Phase 2, Phase 3, Early Phase 1
Parkinsonism post encephalitic
0 Actively Recruiting
Parkinson Disease
0 Actively Recruiting
Carbon Monoxide Poisoning
0 Actively Recruiting
Manganese Poisoning
0 Actively Recruiting
levodopa-driven nausea and vomiting
0 Actively Recruiting

Parcopa Reviews: What are patients saying about Parcopa?

5Patient Review
5/6/2014
Parcopa for Parkinson's Disease
I'm having a lot of trouble finding this particular medicine, and the generic doesn't work as well. My quality of life has really suffered because of it.
4.7Patient Review
7/4/2009
Parcopa for Parkinson's Disease
I was getting this drug through UCB in Georgia, but they sold it. I did well on the medication and would like to know where I can get it through a patient assistant program.
4.3Patient Review
5/3/2009
Parcopa for Parkinson's Disease
I haven't experienced any nausea with this tablet form of the medication, which is great. I really like it so far!
3.7Patient Review
5/27/2010
Parcopa for Parkinson's Disease
I find this treatment to be helpful.

Patient Q&A Section about parcopa

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Parcopa used for?

"This formulation is a treatment for the signs of Parkinson's sickness or similar indications (for example, unsteadiness, solidness, trouble moving). It is believed that Parkinson's malady is activated by too little of a normally happening substance (dopamine) in the cerebrum."

Answered by AI

Is Parcopa the same as Sinemet?

"Carbidopa and levodopa are also used to treat Parkinson's symptoms caused by carbon monoxide poisoning or manganese intoxication. Parcopa is an extended-release version of carbidopa and levodopa."

Answered by AI

How long does it take for Parcopa to work?

"Vitamins containing iron may interfere with the medication's effectiveness. The active ingredients in Sinemet and Parcopa tablets begin to take effect 30 minutes after ingestion."

Answered by AI

Clinical Trials for Parcopa

Have you considered Parcopa clinical trials? We made a collection of clinical trials featuring Parcopa, we think they might fit your search criteria.Go to Trials
Image of University of Kentucky in Lexington, United States.

Peripheral Nerve Tissue Implantation for Parkinson's Disease

45 - 75
All Sexes
Lexington, KY
The investigators propose a Phase I single surgical-center, double-blinded randomized parallel clinical trial involving bilateral autologous peripheral nerve tissue (PNT) delivery into the NBM or the alternate target also affecting cognition in this population, the substantia nigra (SN), to address "repair cell" support of these areas. Twenty-four participants with idiopathic Parkinson's Disease (PD) who have selected, qualified and agreed to receive as standard of care deep brain stimulation (DBS) will be enrolled and randomly allocated to receive bilateral PNT deployment to either the NBM or SN at the time of DBS surgery. Participants will be allocated equally among both assignments over the course of three years (8 Year 1, 10 Year 2, 6 Year 3). Participants will be evaluated for neurocognitive, motoric function, activities of daily living, and quality of life at enrollment before surgery, two-weeks after surgery, and 6, 12, and 24 months after surgery.
Phase 1
Recruiting
University of KentuckyCraig G van Horne, MD, PhD
Image of Austin Clinic PPD in Austin, United States.

LY3962681 for Parkinson's Disease

30 - 80
All Sexes
Austin, TX
The purpose of this study is to evaluate the safety, tolerability, and PK/PD of LY3962681 in healthy volunteers and patients with Parkinson's disease. The study will be comprised of two parts, the Single Ascending Dose (SAD) study and the Multiple Ascending Doses (MAD) study. During the SAD portion of the study, healthy volunteers will receive a single dose of LY3962681 or placebo (artificial cerebrospinal fluid (aCSF), no active drug) given into the spinal fluid. During the MAD portion of the study, patients with Parkinson's disease will receive two doses of either LY3962681 or placebo (aCSF) administered into the spinal fluid. * The treatment period in the SAD study will be 1 day. The treatment period in the MAD study will be 2 days, 12 to 24 weeks apart. * The follow-up period in the SAD study will be up to 52 weeks. The follow-up period in the MAD study will be up to 52 weeks post Dose 2.
Phase 1
Recruiting
Austin Clinic PPDTravis LewisPrevail Therapeutics
Image of Edward Hines Jr. VA Hospital, Hines, IL in Hines, United States.

Non-Invasive Vagal Nerve Stimulation for Parkinson's Disease

50 - 88
All Sexes
Hines, IL
More than 110,000 US Veterans living with Parkinson's disease (PD) currently receive PD-related care and services from the VA. Fall prevention is a priority for Veterans living PD. Gait disturbances are a major cause for functional dependence and the largest risk factor for falls, institutionalization, and death in PD. This SPiRE addresses the need to advance nonpharmacological rehabilitative health care of Veterans and maximizing functional outcomes by developing a non-invasive, neuromodulatory transcutaneous cervical Vagal Nerve Stimulation as an at-home intervention to improve gait and balance. This pilot clinical trial will assist with future efforts and priorities of the VA to prolong independent living and quality of life by minimizing gait and balance dysfunction experienced by Veterans living with PD.
Waitlist Available
Has No Placebo
Edward Hines Jr. VA Hospital, Hines, ILSandra L. Kletzel, PhD BA
Have you considered Parcopa clinical trials? We made a collection of clinical trials featuring Parcopa, we think they might fit your search criteria.Go to Trials
Image of San Francisco VA Medical Center, San Francisco, CA in San Francisco, United States.

Ketamine for Depression in Parkinson's Disease

40 - 80
All Sexes
San Francisco, CA
Parkinson's disease (PD) is a devastating illness that has a growing impact on Veterans. One of the most disabling symptoms is depression, which is common in PD and linked to poor quality of life and higher risk of suicide. Unfortunately, there is a lack of effective treatments for depression in PD. Ketamine, which has rapid and potent antidepressant effects, is a potential option but has not been tested in Veterans with PD. Studies in rodents show that ketamine may not only improve depression in PD, it may target two of the underlying drivers of the disease: (1) reduced neuroplasticity, or the brain's ability to adapt and remodel itself; and (2) elevated inflammation. The investigators are conducting a randomized, placebo-controlled study to examine if a dose of intravenous (IV) ketamine improves depression in Veterans with PD. The investigators will also examine ketamine's effects on neuroplasticity and inflammation, which will help us understand how ketamine works in PD and if it can be a useful treatment for Veterans with the disease. This study will lay groundwork for a larger clinical trial across multiple VA sites.
Phase 2
Recruiting
San Francisco VA Medical Center, San Francisco, CAEllen R Bradley, MD
Image of Hunter Holmes McGuire VA Medical Center, Richmond, VA in Richmond, United States.

Exoskeleton for Parkinson's Disease

18 - 90
All Sexes
Richmond, VA
Physical therapy approaches for balance and walking deficits in Parkinson's disease (PD) have limited effectiveness, with mostly short-lasting benefits. An exoskeleton is a device that straps to the legs and provides a passive force to assist people to better ambulate. The goal of this study is to establish the feasibility and safety of a lightweight exoskeleton on mobility and fall reduction in people with PD. As most PD patients eventually require assistive mobility devices, the exoskeleton represents a new option for increased, mobility, quality of life, and independence. Qualified subjects will come to the clinic twice weekly for six weeks (12 total visits) and wear the exoskeleton device while walking under the supervision of a trained physical therapist. Study staff will also interview participants and assess their PD symptoms, quality of life, and overall mobility. This study hopes to establish exoskeletons as modern, standard of care devices, which allow people with PD to maintain more independent and productive lives.
Recruiting
Has No Placebo
Hunter Holmes McGuire VA Medical Center, Richmond, VAMark S Baron, MD
Image of Stanford Neuroscience Health Center in Stanford, United States.

STN+NBM DBS for Mild Cognitive Impairment in Parkinson's Disease

21 - 80
All Sexes
Stanford, CA
The goal of this clinical trial is to evaluate the safety and tolerability of a novel deep brain stimulation (DBS) of the Subthalamic Nucleus (STN) and Nucleus Basalis of Meynert (NBM) to treat cognitive and cognitive-motor symptoms in individuals with Parkinson's disease. The main question it aims to answer is: Is a combined deep brain stimulation approach targeting the STN and NBM with four DBS leads safe and tolerable for cognitive and cognitive-motor symptoms in individuals with Parkinson's disease with Mild Cognitive Impairment. Ten participants are anticipated to be enrolled. Participants will undergo a modification of the traditional STN DBS approach for motor symptoms of PD. In addition to the two leads placed within the STN, two additional leads will be placed with the NBM for treatment of cognitive and cognitive-motor symptoms. Novel stimulation patterns will be used within the NBM to target cognitive and cognitive-motor symptoms using an investigational software. Participants will be followed over two years while receiving this therapy with assessments at baseline and every six months. Assessments will include a combination of neuropsychological evaluations, cognitive assessments, motor tasks (including gait/walking), and questionnaires to evaluate the treatment. Two different surgical trajectories will be used, with half the cohort randomized to each group. This will allow comparison of the impact of surgical trajectory on the intervention.
Recruiting
Has No Placebo
Stanford Neuroscience Health CenterHelen M Bronte-Stewart, MD MSE
Have you considered Parcopa clinical trials? We made a collection of clinical trials featuring Parcopa, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security